Anti-Hypertensive Drugs Market Set for Rapid Growth, Regional Analysis, Key Players of Anti-Hypertensive Drugs Market include Teva Pharmaceuticals limited (Israel), Sun Pharmaceuticals Industries Limited (India), Dr. Reddy’s Laboratories Ltd. (India), etc. and Trend till 2022
Pune, India -- (SBWIRE) -- 04/11/2018 -- Global Anti-Hypertensive Drugs Market was valued at $32.2 billion in 2015, and is expected to reach $ 38.9 billion by 2022. Thus the market is expected to perform sluggish growth at a CAGR of 2.73% from 2016 to 2022.
Regional Analysis of Global Anti-Hypertensive Drugs Market:
Globally North America is the largest market for global anti-hypertensive drugs. Europe is the second-largest market for global anti-hypertensive drugs. The near future market for anti-hypertensive drugs will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Key Players for Global Anti-Hypertensive Drugs Market:
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc.
Market Scenario:
Anti-hypertensive drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults.
There exact cause of essential hypertension is unknown but is blamed on unhealthy lifestyle and ageing. The major market driving factor for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumors, heart ailments, chronic alcohol use etc. in which anti-hypertensive are used are some of the other factors driving the growth of the market.
The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster's such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2347 .
Segments:
Global anti-hypertensive drugs market has been segmented on the basis of pharmacological class, hypertension type, disease source and Region.
Table Of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter's Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor's
4.1.4 Threat Of New Entrants
5 Global Anti-Hypertensive Drugs Market, By Pharmacological Class
Continued…
Access Discount Page @ https://www.marketresearchfuture.com/check-discount/2347 .
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.